Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 3
1998 9
1999 1
2000 4
2001 6
2002 6
2003 4
2004 1
2005 7
2006 2
2007 11
2008 7
2009 8
2010 9
2011 1
2012 6
2013 7
2014 3
2015 4
2016 6
2017 13
2018 6
2019 6
2020 15
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

142 results
Results by year
Filters applied: . Clear all
Page 1
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Pairon JC, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Cardillo G, Putora PM. Scherpereel A, et al. Among authors: mutti l. Eur Respir J. 2020 Jun 11;55(6):1900953. doi: 10.1183/13993003.00953-2019. Print 2020 Jun. Eur Respir J. 2020. PMID: 32451346
P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma.
Costa C, Indovina P, Mattioli E, Forte IM, Iannuzzi CA, Luzzi L, Bellan C, De Summa S, Bucci E, Di Marzo D, De Feo M, Mutti L, Pentimalli F, Giordano A. Costa C, et al. Among authors: mutti l. Cell Death Dis. 2020 Sep 14;11(9):748. doi: 10.1038/s41419-020-02940-w. Cell Death Dis. 2020. PMID: 32929059 Free PMC article.
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis.
Correale P, Saladino RE, Giannarelli D, Sergi A, Mazzei MA, Bianco G, Giannicola R, Iuliano E, Forte IM, Calandruccio ND, Falzea AC, Strangio A, Nardone V, Pastina P, Tini P, Luce A, Caraglia M, Caracciolo D, Mutti L, Tassone P, Pirtoli L, Giordano A, Tagliaferri P. Correale P, et al. Among authors: mutti l. Cells. 2020 Aug 25;9(9):1964. doi: 10.3390/cells9091964. Cells. 2020. PMID: 32854442 Free PMC article.
PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
Barbarino M, Cesari D, Bottaro M, Luzzi L, Namagerdi A, Bertolino FM, Bellan C, Proietti F, Somma P, Micheli M, de Santi MM, Guazzo R, Mutti L, Pirtoli L, Paladini P, Indovina P, Giordano A. Barbarino M, et al. Among authors: mutti l. J Cell Mol Med. 2020 May;24(10):5565-5577. doi: 10.1111/jcmm.15213. Epub 2020 Apr 17. J Cell Mol Med. 2020. PMID: 32301278 Free PMC article.
Tumour Treating Fields for mesothelioma.
Barbarino M, Bottaro M, Luzzi L, Giordano A, Mutti L. Barbarino M, et al. Among authors: mutti l. Lancet Oncol. 2020 Jan;21(1):e8. doi: 10.1016/S1470-2045(19)30829-0. Lancet Oncol. 2020. PMID: 31908312 No abstract available.
Anti-CTLA-4 therapy for malignant mesothelioma.
Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, Mutti L. Guazzelli A, et al. Among authors: mutti l. Immunotherapy. 2017 Mar;9(3):273-280. doi: 10.2217/imt-2016-0123. Immunotherapy. 2017. PMID: 28231719 Free article. Review.
Immunotherapy advances for mesothelioma treatment.
Bakker E, Guazzelli A, Ashtiani F, Demonacos C, Krstic-Demonacos M, Mutti L. Bakker E, et al. Among authors: mutti l. Expert Rev Anticancer Ther. 2017 Sep;17(9):799-814. doi: 10.1080/14737140.2017.1358091. Epub 2017 Jul 31. Expert Rev Anticancer Ther. 2017. PMID: 28724330 Free article. Review.
Scientific Advances and New Frontiers in Mesothelioma Therapeutics.
Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Mutti L, et al. J Thorac Oncol. 2018 Sep;13(9):1269-1283. doi: 10.1016/j.jtho.2018.06.011. J Thorac Oncol. 2018. PMID: 29966799 Free PMC article. Review.
142 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page